M-CENK

Phase 2Small molecule

IImmunityBio, Inc.

M-CENK is one of 66 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Platinum-Resistant Ovarian CancerRecruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Platinum-Resistant Ovarian CancerPhase 2

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

M-CENK

IImmunityBio, Inc.

Phase 2

1 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Osmitrol

BB. Braun Medical Inc.

Preclinical

—8

Ifex

BBaxter Healthcare Corporation

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Platinum-Resistant Ovarian Cancer

NCT06710288

Q2 2031

Phase 2Not yet recruiting

Prostate Cancer

NCT06765954

Phase 2Not yet recruiting

Immunotherapy

NCT06765902

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT06765954·20 enrolled

Immunotherapy1 trial

Immunotherapy Before and After Surgery

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT06765902·20 enrolled

Platinum-resistant Ovarian Cancer1 trial

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Recruiting·IImmunityBio, Inc.·Phase 2·NCT06710288·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for M-CENK. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — M-CENK compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for M-CENK. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IImmunityBio, Inc.

M-CENK

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2031

Trials by Indication[1]

Prostate Cancer1 trial

Immunotherapy1 trial

Platinum-resistant Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News